The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78

Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation

(2010) P. Perez-Galan et al.   BLOOD

Untangling the unfolded protein response

(2010) Emma L. Davenport et al.   CELL CYCLE

Activation of the Endoplasmic Reticulum Stress-Associated Transcription Factor X Box-Binding Protein-1 Occurs in a Subset of Normal Germinal-Center B Cells and in Aggressive B-Cell Lymphomas with Prognostic Implications

(2009) Olga Balague et al.   AMERICAN JOURNAL OF PATHOLOGY

How I treat mantle cell lymphoma

(2009) M. Ghielmini et al.   BLOOD

2-D PAGE-based comparison of proteasome inhibitor bortezomib in sensitive and resistant mantle cell lymphoma

(2009) Marc Weinkauf et al.   ELECTROPHORESIS

Characterization of the ubiquitin–proteasome system in bortezomib-adapted cells

(2009) T Rückrich et al.   LEUKEMIA

Dysregulation of unfolded protein response partially underlies proapoptotic activity of bortezomib in multiple myeloma cells

(2009) Hongjuan Dong et al.   LEUKEMIA & LYMPHOMA

ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells

(2009) Q. Wang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study

(2008) A. Goy et al.   ANNALS OF ONCOLOGY

Uniparental disomies, homozygous deletions, amplifications, and target genes in mantle cell lymphoma revealed by integrative high-resolution whole-genome profiling

(2008) S. Bea et al.   BLOOD

The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies

(2008) L. Paoluzzi et al.   BLOOD

Molecular basis of bortezomib resistance: proteasome subunit  5 (PSMB5) gene mutation and overexpression of PSMB5 protein

(2008) R. Oerlemans et al.   BLOOD

Dual Targeting of HSC70 and HSP72 Inhibits HSP90 Function and Induces Tumor-Specific Apoptosis

(2008) Marissa V. Powers et al.   CANCER CELL

Targeting Hsp90: small-molecule inhibitors and their clinical development

(2008) Tony Taldone et al.   CURRENT OPINION IN PHARMACOLOGY

Mechanisms of proteasome inhibitor action and resistance in cancer

(2008) David J. McConkey et al.   DRUG RESISTANCE UPDATES

Therapy of Mantle Cell Lymphoma: Current Standards and Future Strategies

(2008) Christian Schmidt et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Point Mutation of the Proteasome  5 Subunit Gene Is an Important Mechanism of Bortezomib Resistance in Bortezomib-Selected Variants of Jurkat T Cell Lymphoblastic Lymphoma/Leukemia Line

(2008) S. Lu et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Novel approaches for the treatment of NHL: Proteasome inhibition and immune modulation

(2008) Owen A. O'Connor et al.   LEUKEMIA & LYMPHOMA

Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma

(2008) David T Yang et al.   Molecular Cancer

Cyclin D1 mediates resistance to apoptosis through upregulation of molecular chaperones and consequent redistribution of cell death regulators

(2008) G Roué et al.   ONCOGENE